Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue’s HiMice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
Menu
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue’s HiMice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

Shareholders

Financial Reports

Delisting from ASX Official List

February 26, 2021
Read More >>

Appendix 4C – quarterly

February 1, 2021
Read More >>
VIEW ALL

Analyst Reports

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

July 27, 2022
Read More »

Biotech Daily May 2019 – Dr Boreham's Crucible

June 13, 2019
Read More »
VIEW ALL

Announcements

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

July 27, 2022
Read More >>

Operational Updates and Management Accounts

February 18, 2022
Read More >>
VIEW ALL
Invitrocue - Contact Us

Are you interested in Invitrocue?
Get in touch with our team.

All enquiries are welcome. We look forward to hearing from you!

CONTACT US

GET IN TOUCH

51 Science Park Road, #01-11/13
The Aries, Singapore Science Park II
Singapore 117586

+65 6460 0497

contact@invitrocue.com

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Twitter Facebook-f Linkedin-in Youtube

© Copyright 2023 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings